Tag - SCPH

Developments

FDA accepts scPharmaceuticals sNDA to expand heart failure drug indication

scPharmaceuticals (NASDAQ:SCPH) has announced FDA approval of its supplemental NDA (sNDA) for FUROSCIX, expanding its indication to New York Heart Association (NYHA) Class IV chronic heart failure patients. Previously...

August 12, 2024

Markets

SVB ups scPharmaceuticals on FDA approval of Furoscix

SVB Securities upgraded scPharmaceuticals (NASDAQ:SCPH) to “outperform” from “market perform” and raised its price target to $11 from $6 after FDA approval of Furoscix for treatment of congestion in chronic heart...

October 11, 2022

Markets

Maxim starts scPharmaceuticals at buy; PT $10

Maxim Group initiated coverage of scPharmaceuticals (NASDQ:SCPH) with a “buy” rating and price target of $10. The stock closed at $4.89 on Aug. 2. scPharmaceuticals is a late-stage pre-commercial company developing...

August 2, 2022

Markets

SVB Leerink starts scPharmaceuticals at MP; PT $6

SVB Leerink launched coverage of scPharmaceuticals (NASDAQ:SCPH) with a “market perform” rating sum-of-the-parts PT of $6. The stock closed at $5.95 on Sept. 8. Analyst Roanna Ruiz, Ph.D., writes that, among other...

September 9, 2021

Tag - SCPH

FDA accepts scPharmaceuticals sNDA to expand heart failure drug indication

SVB ups scPharmaceuticals on FDA approval of Furoscix

Maxim starts scPharmaceuticals at buy; PT $10

SVB Leerink starts scPharmaceuticals at MP; PT $6

General

More